Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A

Journal of Experimental Medicine

Volumn 210, Issue 13, 2013, Pages 2851-2872

  Lotti, Fiorenza ^a   Jarrar, Awad M ^a   Pai, Rish K ^a   Hitomi, Masahiro ^a,b   Lathia, Justin ^a,b,e   Mace, Adam ^a   Gantt, Gerald A ^a   Sukhdeo, Kumar ^a   DeVecchio, Jennifer ^a   Vasanji, Amit ^c   Leahy, Patrick ^d   Hjelmeland, Anita B ^a   Kalady, Matthew F ^a,b   Rich, Jeremy N ^a,b,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c ImageIQ   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e National Center for Regenerative Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; OXALIPLATIN; PANITUMUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INITIATING CELL; CANCER RESISTANCE; CELL ACTIVATION; CELL COUNT; CELL INVASION; CELL RENEWAL; CELL STIMULATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG TARGETING; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SEPARATION; CHEMOKINES; COCULTURE TECHNIQUES; COLORECTAL NEOPLASMS; CYTOKINES; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; MICE; NEOPLASM TRANSPLANTATION; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84890812467     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20131195     Document Type: Article

References (102)

1. Acharyya, S., T. Oskarsson, S. Vanharanta, S. Malladi, J. Kim, P.G. Morris, K. Manova-Todorova, M. Leversha, N. Hogg, V.E. Seshan, et al. 2012. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 150:165-178. http://dx.doi.org/10.1016/j.cell.2012.04.042
2. Allinen, M., R. Beroukhim, L. Cai, C. Brennan, J. Lahti-Domenici, H. Huang, D. Porter, M. Hu, L. Chin, A. Richardson, et al. 2004. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 6:17-32. http://dx.doi.org/10.1016/j.ccr.2004.06.010
3. American Cancer Society. 2011. American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. http://www.cancer.org/research/cancerfactsstatistics/colorectal-cancer-facts-figures
4. Arnold, D., and T. Seufferlein. 2010. Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut. 59:838-858. http://dx.doi.org/10.1136/gut.2009.196006
5. Barcellos-Hoff, M.H., and S.A. Ravani. 2000. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60:1254-1260.
6. Barker, N., J.H. van Es, J. Kuipers, P. Kujala, M. van den Born, M. Cozijnsen, A. Haegebarth, J. Korving, H. Begthel, P.J. Peters, and H. Clevers. 2007. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 449:1003-1007. http://dx.doi.org/10.1038/nature06196
7. Barker, N., R.A. Ridgway, J.H. van Es, M. van de Wetering, H. Begthel, M. van den Born, E. Danenberg, A.R. Clarke, O.J. Sansom, and H. Clevers. 2009. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 457:608-611. http://dx.doi.org/10.1038/nature07602
8. Bissell, M.J., and M.A. Labarge. 2005. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell. 7:17-23.
9. Blache, P., M. van de Wetering, I. Duluc, C. Domon, P. Berta, J.N. Freund, H. Clevers, and P. Jay. 2004. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J. Cell Biol. 166:37-47. http://dx.doi.org/10.1083/jcb.200311021
10. Blanpain, C. 2013. Tracing the cellular origin of cancer. Nat. Cell Biol. 15:126-134. http://dx.doi.org/10.1038/ncb2657
11. Bonnet, D., and J.E. Dick. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3:730-737. http://dx.doi.org/10.1038/nm0797-730
12. Bruchard, M., G. Mignot, V. Derangère, F. Chalmin, A. Chevriaux, F. Végran, W. Boireau, B. Simon, B. Ryffel, J.L. Connat, et al. 2013. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19:57-64. http://dx.doi.org/10.1038/nm.2999
13. Calon, A., E. Espinet, S. Palomo-Ponce, D.V. Tauriello, M. Iglesias, M.V. Céspedes, M. Sevillano, C. Nadal, P. Jung, X.H. Zhang, et al. 2012. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell. 22:571-584. http://dx.doi.org/10.1016/j.ccr.2012.08.013
14. Chung, A.S., X. Wu, G. Zhuang, H. Ngu, I. Kasman, J. Zhang, J.M. Vernes, Z. Jiang, Y.G. Meng, F.V. Peale, et al. 2013. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 19:1114-1123. http://dx.doi.org/10.1038/nm.3291
15. Crawford, Y., I. Kasman, L. Yu, C. Zhong, X. Wu, Z. Modrusan, J. Kaminker, and N. Ferrara. 2009. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 15:21-34. http://dx.doi.org/10.1016/j.ccr.2008.12.004
16. Dalerba, P., S.J. Dylla, I.K. Park, R. Liu, X. Wang, R.W. Cho, T. Hoey, A. Gurney, E.H. Huang, D.M. Simeone, et al. 2007. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA. 104:10158-10163. http://dx.doi.org/10.1073/pnas.0703478104
17. Dallas, N.A., L. Xia, F. Fan, M.J. Gray, P. Gaur, G. van Buren II, S. Samuel, M.P. Kim, S.J. Lim, and L.M. Ellis. 2009. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 69:1951-1957. http://dx.doi.org/10.1158/0008-5472.CAN-08-2023
18. De Wever, O., and M. Mareel. 2002. Role of myofibroblasts at the invasion front. Biol. Chem. 383:55-67. http://dx.doi.org/10.1515/BC.2002.006
19. Deng, S., X. Yang, H. Lassus, S. Liang, S. Kaur, Q. Ye, C. Li, L.P. Wang, K.F. Roby, S. Orsulic, et al. 2010. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE. 5:e10277. http://dx.doi.org/10.1371/journal.pone.0010277
20. Desmoulière, A., C. Guyot, and G. Gabbiani. 2004. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int. J. Dev. Biol. 48:509-517. http://dx.doi.org/10.1387/ijdb.041802ad
21. Du, L., H. Wang, L. He, J. Zhang, B. Ni, X. Wang, H. Jin, N. Cahuzac, M. Mehrpour, Y. Lu, and Q. Chen. 2008. CD44 is of functional importance for colorectal cancer stem cells. Clin. Cancer Res. 14:6751-6760. http://dx.doi.org/10.1158/1078-0432.CCR-08-1034
22. Dvorak, H.F. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315:1650-1659. http://dx.doi.org/10.1056/NEJM198612253152606
23. Dylla, S.J., L. Beviglia, I.K. Park, C. Chartier, J. Raval, L. Ngan, K. Pickell, J. Aguilar, S. Lazetic, S. Smith-Berdan, et al. 2008. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE. 3:e2428. http://dx.doi.org/10.1371/journal.pone.0002428
24. Edge, S., D. Byrd, M. Carducci, and C. Compton. 2009. AJCC Cancer Staging Manual. Springer, New York.
25. Elsaba, T.M., L. Martinez-Pomares, A.R. Robins, S. Crook, R. Seth, D. Jackson, A. McCart, A.R. Silver, I.P. Tomlinson, and M. Ilyas. 2010. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS ONE. 5:e10714. http://dx.doi.org/10.1371/journal.pone.0010714
26. Erez, N., M. Truitt, P. Olson, S.T. Arron, and D. Hanahan. 2010. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell. 17:135-147. http://dx.doi.org/10.1016/j.ccr.2009.12.041
27. Fang, D.D., Y.J. Kim, C.N. Lee, S. Aggarwal, K. McKinnon, D. Mesmer, J. Norton, C.E. Birse, T. He, S.M. Ruben, and P.A. Moore. 2010. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br. J. Cancer. 102:1265-1275. http://dx.doi.org/10.1038/sj.bjc.6605610
28. Gemei, M., P. Mirabelli, R. Di Noto, C. Corbo, A. Iaccarino, A. Zamboli, G. Troncone, G. Galizia, E. Lieto, L. Del Vecchio, and F. Salvatore. 2013. CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. Cancer. 119:729-738. http://dx.doi.org/10.1002/cncr.27794
29. Gilbert, L.A., and M.T. Hemann. 2010. DNA damage-mediated induction of a chemoresistant niche. Cell. 143:355-366. http://dx.doi.org/10.1016/j.cell.2010.09.043
30. Gilbert, L.A., and M.T. Hemann. 2011. Chemotherapeutic resistance: surviving stressful situations. Cancer Res. 71:5062-5066. http://dx.doi.org/10.1158/0008-5472.CAN-11-0277
31. Gonda, T.A., A. Varro, T.C. Wang, and B. Tycko. 2010. Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anticancer therapy? Semin. Cell Dev. Biol. 21:2-10. http://dx.doi.org/10.1016/j.semcdb.2009.10.001
32. Grivennikov, S.I., K. Wang, D. Mucida, C.A. Stewart, B. Schnabl, D. Jauch, K. Taniguchi, G.Y. Yu, C.H. Osterreicher, K.E. Hung, et al. 2012. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 491:254-258.
33. Grum-Schwensen, B., J. Klingelhofer, C.H. Berg, C. El-Naaman, M. Grigorian, E. Lukanidin, and N. Ambartsumian. 2005. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. 65:3772-3780. http://dx.doi.org/10.1158/0008-5472. CAN-04-4510
34. Guo, W., Z. Keckesova, J.L. Donaher, T. Shibue, V. Tischler, F. Reinhardt, S. Itzkovitz, A. Noske, U. Zürrer-Härdi, G. Bell, et al. 2012. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 148:1015-1028. http://dx.doi.org/10.1016/j.cell.2012.02.008
35. Hao, M., L. Zhang, G. An, H. Meng, Y. Han, Z. Xie, Y. Xu, C. Li, Z. Yu, H. Chang, and L. Qiu. 2011. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk. Lymphoma. 52:1787-1794. http://dx.doi.org/10.3109/10428194.2011.576791
36. Hellevik, T., I. Pettersen, V. Berg, J. Bruun, K. Bartnes, L.T. Busund, A. Chalmers, R. Bremnes, and I. Martinez-Zubiaurre. 2013. Changes in the Secretory Profile of NSCLC-Associated Fibroblasts after Ablative Radiotherapy: Potential Impact on Angiogenesis and Tumor Growth. Transl Oncol. 6:66-74.
37. Hölzel, M., A. Bovier, and T. Tüting. 2013. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat. Rev. Cancer. 13:365-376. http://dx.doi.org/10.1038/nrc3498
38. Horst, D., L. Kriegl, J. Engel, T. Kirchner, and A. Jung. 2009. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 27:844-850. http://dx.doi.org/10.1080/07357900902744502
39. Hu, Y., and G.K. Smyth. 2009. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods. 347:70-78. http://dx.doi.org/10.1016/j.jim.2009.06.008
40. Huang, E.H., M.J. Hynes, T. Zhang, C. Ginestier, G. Dontu, H. Appelman, J.Z. Fields, M.S. Wicha, and B.M. Boman. 2009. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 69:3382-3389. http://dx.doi.org/10.1158/0008-5472. CAN-08-4418
41. Hueber, W., D.D. Patel, T. Dryja, A.M. Wright, I. Koroleva, G. Bruin, C. Antoni, Z. Draelos, M.H. Gold, P. Durez, et al; Psoriasis Study Group; Rheumatoid Arthritis Study Group; Uveitis Study Group. 2010. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2:52ra72. http://dx.doi.org/10.1126/scitranslmed.3001107
42. Hyun, Y.S., D.S. Han, A.R. Lee, C.S. Eun, J. Youn, and H.Y. Kim. 2012. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis. 33:931-936. http://dx.doi.org/10.1093/carcin/bgs106
43. Jay, P., P. Berta, and P. Blache. 2005. Expression of the carcinoembryonic antigen gene is inhibited by SOX9 in human colon carcinoma cells. Cancer Res. 65:2193-2198. http://dx.doi.org/10.1158/0008-5472. CAN-04-1484
44. Lakshman, M., V. Subramaniam, U. Rubenthiran, and S. Jothy. 2004. CD44 promotes resistance to apoptosis in human colon cancer cells. Exp. Mol. Pathol. 77:18-25. http://dx.doi.org/10.1016/j.yexmp.2004.03.002
45. Lakshman, M., V. Subramaniam, S. Wong, and S. Jothy. 2005. CD44 promotes resistance to apoptosis in murine colonic epithelium. J. Cell. Physiol. 203:583-588. http://dx.doi.org/10.1002/jcp.20260
46. Leonardi, C., R. Matheson, C. Zachariae, G. Cameron, L. Li, E. Edson-Heredia, D. Braun, and S. Banerjee. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366:1190-1199. http://dx.doi.org/10.1056/NEJMoa1109997
47. Li, H.J., F. Reinhardt, H.R. Herschman, and R.A. Weinberg. 2012. Cancerstimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov. 2:840-855. http://dx.doi.org/10.1158/2159-8290.CD-12-0101
48. Lieubeau, B., L. Garrigue, I. Barbieux, K. Meflah, and M. Gregoire. 1994. The role of transforming growth factor beta 1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res. 54:6526-6532.
49. Liu, S., C. Ginestier, S.J. Ou, S.G. Clouthier, S.H. Patel, F. Monville, H. Korkaya, A. Heath, J. Dutcher, C.G. Kleer, et al. 2011. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71:614-624. http://dx.doi.org/10.1158/0008-5472.CAN-10-0538
50. Lu, J., X. Ye, F. Fan, L. Xia, R. Bhattacharya, S. Bellister, F. Tozzi, E. Sceusi, Y. Zhou, I. Tachibana, et al. 2013. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell. 23:171-185. http://dx.doi.org/10.1016/j.ccr.2012.12.021
51. Magee, J.A., E. Piskounova, and S.J. Morrison. 2012. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 21:283-296. http://dx.doi.org/10.1016/j.ccr.2012.03.003
52. Markowitz, S.D., and M.M. Bertagnolli. 2009. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 361:2449-2460. http://dx.doi.org/10.1056/NEJMra0804588
53. Markowitz, S., J. Wang, L. Myeroff, R. Parsons, L. Sun, J. Lutterbaugh, R.S. Fan, E. Zborowska, K.W. Kinzler, B. Vogelstein, et al. 1995. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 268:1336-1338. http://dx.doi.org/10.1126/science.7761852
54. Matsunaga, T., N. Takemoto, T. Sato, R. Takimoto, I. Tanaka, A. Fujimi, T. Akiyama, H. Kuroda, Y. Kawano, M. Kobune, et al. 2003. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9:1158-1165. http://dx.doi.org/10.1038/nm909
55. Medema, J.P., and L. Vermeulen. 2011. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature. 474:318-326. http://dx.doi.org/10.1038/nature10212
56. Medzhitov, R., and T. Horng. 2009. Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 9:692-703. http://dx.doi.org/10.1038/nri2634
57. Micke, P., and A. Ostman. 2004. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer. 45(Suppl 2): S163-S175. http://dx.doi.org/10.1016/j.lungcan.2004.07.977
58. Nakasone, E.S., H.A. Askautrud, T. Kees, J.H. Park, V. Plaks, A.J. Ewald, M. Fein, M.G. Rasch, Y.X. Tan, J. Qiu, et al. 2012. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 21:488-503. http://dx.doi.org/10.1016/j.ccr.2012.02.017
59. Nakayama, H., H. Enzan, E. Miyazaki, and M. Toi. 2002. Alpha smooth muscle actin positive stromal cells in gastric carcinoma. J. Clin. Pathol. 55:741-744. http://dx.doi.org/10.1136/jcp.55.10.741
60. O'Brien, C.A., A. Pollett, S. Gallinger, and J.E. Dick. 2007. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106-110. http://dx.doi.org/10.1038/nature05372
61. Ogino, S., C.S. Fuchs, and E. Giovannucci. 2012. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev. Mol. Diagn. 12:621-628. http://dx.doi.org/10.1586/erm.12.46
62. Ohata, H., T. Ishiguro, Y. Aihara, A. Sato, H. Sakai, S. Sekine, H. Taniguchi, T. Akasu, S. Fujita, H. Nakagama, and K. Okamoto. 2012. Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells. Cancer Res. 72:5101-5110. http://dx.doi.org/10.1158/0008-5472.CAN-11-3812
63. Olumi, A.F., G.D. Grossfeld, S.W. Hayward, P.R. Carroll, T.D. Tlsty, and G.R. Cunha. 1999. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59:5002-5011.
64. Orimo, A., and R.A. Weinberg. 2007. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol. Ther. 6:618-619.
65. Orimo, A., P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson, and R.A. Weinberg. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121:335-348. http://dx.doi.org/10.1016/j.cell.2005.02.034
66. Papp, K.A., C. Leonardi, A. Menter, J.P. Ortonne, J.G. Krueger, G. Kricorian, G. Aras, J. Li, C.B. Russell, E.H. Thompson, and S. Baumgartner. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366:1181-1189. http://dx.doi.org/10.1056/NEJMoa1109017
67. Park, J.E., M.C. Lenter, R.N. Zimmermann, P. Garin-Chesa, L.J. Old, and W.J. Rettig. 1999. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 274:36505-36512. http://dx.doi.org/10.1074/jbc.274.51.36505
68. Park, J.J., J.H. Kwon, S.H. Oh, J. Choi, C.M. Moon, J.B. Ahn, S.P. Hong, J.H. Cheon, T.I. Kim, H. Kim, and W.H. Kim. 2012. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer. Mol. Carcinog. 10.1002/mc.21971.
69. Peñuelas, S., J. Anido, R.M. Prieto-Sánchez, G. Folch, I. Barba, I. Cuartas, D. García-Dorado, M.A. Poca, J. Sahuquillo, J. Baselga, and J. Seoane. 2009. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 15:315-327. http://dx.doi.org/10.1016/j.ccr.2009.02.011
70. Porter, D.C., E. Farmaki, S. Altilia, G.P. Schools, D.K. West, M. Chen, B.D. Chang, A.T. Puzyrev, C.U. Lim, R. Rokow-Kittell, et al. 2012. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumorpromoting paracrine activities. Proc. Natl. Acad. Sci. USA. 109:13799-13804. http://dx.doi.org/10.1073/pnas.1206906109
71. Ricci-Vitiani, L., D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle, and R. De Maria. 2007. Identification and expansion of human coloncancer-initiating cells. Nature. 445:111-115. http://dx.doi.org/10.1038/nature05384
72. Ricci-Vitiani, L., E. Fabrizi, E. Palio, and R. De Maria. 2009. Colon cancer stem cells. J. Mol. Med. 87:1097-1104. http://dx.doi.org/10.1007/s00109-009-0518-4
73. Rønnov-Jessen, L., O.W. Petersen, and M.J. Bissell. 1996. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 76:69-125.
74. Sadanandam, A., C.A. Lyssiotis, K. Homicsko, E.A. Collisson, W.J. Gibb, S. Wullschleger, L.C. Ostos, W.A. Lannon, C. Grotzinger, M. Del Rio, et al. 2013. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19:619-625. http://dx.doi.org/10.1038/nm.3175
75. Sanchez, J.A., L. Krumroy, S. Plummer, P. Aung, A. Merkulova, M. Skacel, K.L. DeJulius, E. Manilich, J.M. Church, G. Casey, and M.F. Kalady. 2009. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br. J. Surg. 96:1196-1204. http://dx.doi.org/10.1002/bjs.6683
76. Sappino, A.P., O. Skalli, B. Jackson, W. Schürch, and G. Gabbiani. 1988. Smooth-muscle differentiation in stromal cells of malignant and nonmalignant breast tissues. Int. J. Cancer. 41:707-712. http://dx.doi.org/10.1002/ijc.2910410512
77. Sato, T., J.H. van Es, H.J. Snippert, D.E. Stange, R.G. Vries, M. van den Born, N. Barker, N.F. Shroyer, M. van de Wetering, and H. Clevers. 2011. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature. 469:415-418. http://dx.doi.org/10.1038/nature09637
78. Schäfer, M., and S. Werner. 2008. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 9:628-638. http://dx.doi.org/10.1038/nrm2455
79. Schuijers, J., and H. Clevers. 2012. Adult mammalian stem cells: the role of Wnt, Lgr5 and R-spondins. EMBO J. 31:2685-2696. http://dx.doi.org/10.1038/emboj.2012.149
80. Schwitalla, S., A.A. Fingerle, P. Cammareri, T. Nebelsiek, S.I. Göktuna, P.K. Ziegler, O. Canli, J. Heijmans, D.J. Huels, G. Moreaux, et al. 2013. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 152:25-38. http://dx.doi.org/10.1016/j.cell.2012.12.012
81. Serini, G., and G. Gabbiani. 1999. Mechanisms of myofibroblast activity and phenotypic modulation. Exp. Cell Res. 250:273-283. http://dx.doi.org/10.1006/excr.1999.4543
82. Shaked, Y., A. Ciarrocchi, M. Franco, C.R. Lee, S. Man, A.M. Cheung, D.J. Hicklin, D. Chaplin, F.S. Foster, R. Benezra, and R.S. Kerbel. 2006. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 313:1785-1787. http://dx.doi.org/10.1126/science.1127592
83. Shaked, Y., E. Henke, J.M. Roodhart, P. Mancuso, M.H. Langenberg, M. Colleoni, L.G. Daenen, S. Man, P. Xu, U. Emmenegger, et al. 2008. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 14:263-273. http://dx.doi.org/10.1016/j.ccr.2008.08.001
84. Shmelkov, S.V., J.M. Butler, A.T. Hooper, A. Hormigo, J. Kushner, T. Milde, R. St Clair, M. Baljevic, I. White, D.K. Jin, et al. 2008. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118:2111-2120.
85. Shree, T., O.C. Olson, B.T. Elie, J.C. Kester, A.L. Garfall, K. Simpson, K.M. Bell-McGuinn, E.C. Zabor, E. Brogi, and J.A. Joyce. 2011. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 25:2465-2479. http://dx.doi.org/10.1101/gad.180331.111
86. Straussman, R., T. Morikawa, K. Shee, M. Barzily-Rokni, Z.R. Qian, J. Du, A. Davis, M.M. Mongare, J. Gould, D.T. Frederick, et al. 2012. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487:500-504. http://dx.doi.org/10.1038/nature11183
87. Sugimoto, H., T.M. Mundel, M.W. Kieran, and R. Kalluri. 2006. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 5:1640-1646. http://dx.doi.org/10.4161/cbt.5.12.3354
88. Takahashi, K., and S. Yamanaka. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663-676. http://dx.doi.org/10.1016/j.cell.2006.07.024
89. Takahashi, H., H. Ishii, N. Nishida, I. Takemasa, T. Mizushima, M. Ikeda, T. Yokobori, K. Mimori, H. Yamamoto, M. Sekimoto, et al. 2011. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann. Surg. Oncol. 18:1166-1174. http://dx.doi.org/10.1245/s10434-010-1373-9
90. Todaro, M., M.P. Alea, A.B. Di Stefano, P. Cammareri, L. Vermeulen, F. Iovino, C. Tripodo, A. Russo, G. Gulotta, J.P. Medema, and G. Stassi. 2007. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 1:389-402. http://dx.doi.org/10.1016/j.stem.2007.08.001
91. Tuxhorn, J.A., S.J. McAlhany, F. Yang, T.D. Dang, and D.R. Rowley. 2002. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 62:6021-6025.
92. Vermeulen, L., M. Todaro, F. de Sousa Mello, M.R. Sprick, K. Kemper, M. Perez Alea, D.J. Richel, G. Stassi, and J.P. Medema. 2008. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl. Acad. Sci. USA. 105:13427-13432. http://dx.doi.org/10.1073/pnas.0805706105
93. Vermeulen, L., F. De Sousa E Melo, M. van der Heijden, K. Cameron, J.H. de Jong, T. Borovski, J.B. Tuynman, M. Todaro, C. Merz, H. Rodermond, et al. 2010. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12:468-476. http://dx.doi.org/10.1038/ncb2048
94. Wang, H., J.D. Lathia, Q. Wu, J. Wang, Z. Li, J.M. Heddleston, C.E. Eyler, J. Elderbroom, J. Gallagher, J. Schuschu, et al. 2009. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells. 27:2393-2404. http://dx.doi.org/10.1002/stem.188
95. Washington, M.K., J. Berlin, P. Branton, L.J. Burgart, D.K. Carter, P.L. Fitzgibbons, K. Halling, W. Frankel, J. Jessup, S. Kakar, et al; Members of the Cancer Committee, College of American Pathologists. 2009. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch. Pathol. Lab. Med. 133:1539-1551.
96. Weaver, V.M., S. Lelièvre, J.N. Lakins, M.A. Chrenek, J.C. Jones, F. Giancotti, Z. Werb, and M.J. Bissell. 2002. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell. 2:205-216. http://dx.doi.org/10.1016/S1535-6108(02)00125-3
97. Winder, T., and H.J. Lenz. 2010. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology. 138:2163-2176. http://dx.doi.org/10.1053/j.gastro.2010.02.005
98. Worthley, D.L., A.S. Giraud, and T.C. Wang. 2010. Stromal fibroblasts in digestive cancer. Cancer Microenviron. 3:117-125. http://dx.doi.org/10.1007/s12307-009-0033-8
99. Wu, S., K.J. Rhee, E. Albesiano, S. Rabizadeh, X. Wu, H.R. Yen, D.L. Huso, F.L. Brancati, E. Wick, F. McAllister, et al. 2009. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15:1016-1022. http://dx.doi.org/10.1038/nm.2015
100. Xing, F., J. Saidou, and K. Watabe. 2010. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed). 15:166-179. http://dx.doi.org/10.2741/3613
101. Yamauchi, K., M. Yang, K. Hayashi, P. Jiang, N. Yamamoto, H. Tsuchiya, K. Tomita, A.R. Moossa, M. Bouvet, and R.M. Hoffman. 2008. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 68:516-520. http://dx.doi.org/10.1158/0008-5472.CAN-07-3063
102. Yeung, T.M., S.C. Gandhi, J.L. Wilding, R. Muschel, and W.F. Bodmer. 2010. Cancer stem cells from colorectal cancer-derived cell lines. Proc. Natl. Acad. Sci. USA. 107:3722-3727. http://dx.doi.org/10.1073/pnas.0915135107